Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Tuesday, October 13, 2026

Back to today

From X

@kevin__mak

Kevin Mak on X

$ABVX We've been here before, about three months ago. Price is controlling the narrative again. In June people extrapolated a handful of malignancy cases into a broken thesis, the stock fell 43%, and then erased a month of losses in a single day when the next data landed. Nothing about the asset changed in either direction. I think the same thing is happening now. The price is lower, so people have decided shareholders are doomed and nobody is ever going to buy the business. The fair argument against me is that the probability of a takeout has fallen, because it hasn't happened yet. List your house, get no bids in 60 days, and that tells you something about your asking price. Silence is information. But big pharma M&A is a market with half a dozen real buyers, competing priorities, and internal politics. Deals come together in weeks or in years. The signal from "no deal yet" is extremely noisy, and people are treating it as a clean efficient market. I think the bigger problem is what shareholders were assuming in the first place. If you expected a $180-200 takeout within three months, at today's price that is a 78% return in a quarter. Call it 50/50 to be "conservative" and you are still assuming roughly 39% a quarter or 270% annualized. (Change the numbers to levels a month ago and you still get the same directional craziness) So the problem was never the price target. Targets have a defensible basis. The problem is the clock. My view: $150-200 over the next 18 months, either from a buyout or from a credible launch trajectory. From here that is 25-50% annualized, which is a number a portfolio can be built on. Roughly the same price everyone else is talking about. I just don't have the same timeline expectation. If a buyout comes sooner, that is the better outcome, not just the faster one. The asset is worth more inside a company that already has a GI salesforce than it is standalone. Disclosure: Creek Drive and its affiliated funds hold a long position in ABVX. Views expressed are current opinions for informational and educational purposes only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future results. See the disclosures link in bio for more important information.
@KEDM_COM

KEDM.com on X

Voss Capital has been increasing its position in Euronet Worldwide $EEFT and sending angry letters, pushing the company to review strategic alternatives. Despite almost all fundamentals moving in the right direction, Euronet's share price had a horrible 2025, mostly on (fears of) increasing competition from digital-first rivals such as Wise and Remitly. Voss argues that parts like payment processing and money transfer could be valued more highly on their own. A full sale could deliver even more (100%+ potential), as it will also monetize Euronet's global licenses and cash generation. Also, it is worth noting that Euronet has been (and continues to be) a true share cannibal.

Investor Letters

All letters

Vicor Update, Part Two

Vicor uses ITC exclusion-order cases to license power-module patents, with published royalty multipliers rising from 1.0x before filing to…

VICR $10B
CV's Substack 4 clicks

Expert Call | Nebius

Nebius’s 1 GW annual active-capacity target from 2027 is realistic, according to a former product manager, with greenfield data centers…

NBIS $56B
P Equity Research 4 clicks
PTRN · short

Pattern Group INC

Pattern Group is a fragile consumer business targeted on the short side.

PTRN $3.1B
Value Investors Club 3 clicks

“Is Ralph Lauren Still Relevant?”

Ralph Lauren’s 2017 CEO change put Patrice Louvet in charge of reversing nine quarters of same-store sales declines and restoring the…

RL $22B
TSOH Investment Research 1 click

Deep Dive: Inter & Co

Inter & Co, Brazil’s second-largest neobank, grew over 20% with controlled delinquencies and 15% book-value compounding while trading at…

INTR $3B
Capitalist Letters 7 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 52 of 235

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.